RecruitMe

Dr. Gary Schwartz, MD

Claim this profile

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

Studies Cancer
Studies Solid Tumors
14 reported clinical trials
37 drugs studied

Area of expertise

1Cancer
Gary Schwartz, MD has run 4 trials for Cancer. Some of their research focus areas include:
Stage IV
NF1 positive
KEAP1/NRF2 positive
2Solid Tumors
Gary Schwartz, MD has run 3 trials for Solid Tumors. Some of their research focus areas include:
Stage IV
Stage III
TP53 negative

Affiliated Hospitals

Image of trial facility.
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
Image of trial facility.
Columbia University Medical Center

Clinical Trials Gary Schwartz, MD is currently running

Image of trial facility.

OBT076

for Advanced Cancer

The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to target cancer cells and deliver an anti-cancer drug. OBT076 is composed of an antibody that targets the CD205 protein on cancer cells and delivers an anti-cancer drug which can kill them. OBT076 is an "Investigational Drug", which means that it is still being studied and has not yet been approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) or any other regulatory authorities to be prescribed by doctors for the treatment of metastatic or recurrent solid tumors. The use of OBT076 in this study is investigational. This is a Phase I research study designed to look at several dose levels of the study drug to find the highest dose level that is safe and well-tolerated (does not cause unacceptable side effects), and to examine the effects of the study drug in a small group of research participants. The study will also look at the effectiveness of OBT076 as an anti-cancer therapy. Once the optimal dose is determined and safety is assessed, additional research participants will be treated at the optimal dose level to further evaluate safety and effectiveness.
Recruiting1 award Phase 115 criteria
Image of trial facility.

Spiration Valve System

for Emphysema

This is a single-arm, prospective, multi-center, Registry study to evaluate the long-term safety and effectiveness of the Spiration Valve System (SVS) for the treatment of severe emphysema in a post-market setting.
Recruiting1 award N/A2 criteria

More about Gary Schwartz, MD

Clinical Trial Related2 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Gary Schwartz, MD has experience with
  • OBT076
  • Placebo
  • AL102
  • SPH4336
  • Atezolizumab
  • Bevacizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Gary Schwartz, MD specialize in?
Is Gary Schwartz, MD currently recruiting for clinical trials?
Are there any treatments that Gary Schwartz, MD has studied deeply?
What is the best way to schedule an appointment with Gary Schwartz, MD?
What is the office address of Gary Schwartz, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security